China Releases First AI Brain-Computer Interface Standard

China has approved and released its first standard integrating artificial intelligence with brain-computer interface (BCI) technology, a move regulators describe as the world’s first medical device product standard governing EEG datasets used to train AI algorithms. The standard, designated YY/T 2029-2026, was announced by the National Medical Products Administration (NMPA) and takes effect September 1, 2027, according to Xinhua News.

The standard is officially titled “Brain-computer interface medical devices - Quality requirements and evaluation methods for EEG datasets used for artificial intelligence algorithms.” It is both the world’s first BCI medical device product standard employing AI to process EEG data and China’s third BCI medical device industry standard overall.

Context: Why a Standard, Why Now

BCI technology establishes a direct communication channel between the brain and external devices, used to assist, enhance, or restore sensory and motor functions. China has elevated the field as a strategic priority, designating it one of six future industries in its 15th Five-Year Plan and positioning it as a national economic growth engine.

The market has responded accordingly. China’s BCI market reached 3.2 billion yuan in 2024, up 18.8% year over year, and is projected to reach 5.58 billion yuan by 2027. As of early 2026, China held 2,041 BCI-related patents, more than 90% of them invention patents, with 391 filed in 2024 alone.

But rapid growth brought a familiar problem: fragmentation. According to People’s Daily, EEG-collecting devices vary widely - some use 64 channels, others 128 or 256, and sampling frequencies range from as low as 2 Hz to as high as 1,000 Hz. The absence of unified data rules, the paper noted, makes datasets like “files in different dialects,” hard to compare and reuse.

The NMPA framed the stakes in terms of patient safety. BCI medical devices, it said, are like intelligent machines that read brain signals and must learn from large volumes of EEG data to train AI algorithms to accurately understand a patient’s intent - a process that concerns not only treatment efficacy but also patient safety risk.

What the New Standard Covers

According to the NMPA announcement (Announcement No. 79 of 2026, dated August 24 and publicized September 14), the standard sets full-process technical requirements and testing methods covering data collection, signal processing, data labeling, storage, and access. Its core dimensions include electrode information, collection conditions, time synchronization, experimental paradigms, dataset content, metadata specifications, and decoding performance evaluation.

The standard applies to datasets used in the research, development, production, and quality control of BCI medical devices where AI algorithms post-process EEG signals. In practice, it establishes a unified quality benchmark - elevating data quality requirements from the academic research level to a compliance threshold for medical device market approval.

“This newly released standard draws a unified quality ruler for the ‘data fuel’ of BCI AI algorithms,” the NMPA said, according to Guangming Net, “elevating data quality requirements from the academic research level to a compliance threshold for medical device market approval, shoring up the safety and efficacy foundation of BCI products from the source.”

The drafting bodies included the China National Institutes for Food and Drug Control, the NMPA Medical Device Technical Review Center, and the Shanghai Medical Device Testing Institute. To support innovation and meet urgent industry demand, the NMPA used an expedited procedure for the standard’s project initiation and approval.

Three Standards, One System

This is China’s third BCI medical device industry standard. The first two, both released in 2025, were a terminology standard (YY/T 1987-2025), which took effect January 1, 2026, and a standard covering sensing and response performance testing methods for implantable neurostimulators.

Together with the new AI dataset standard, the three cover the core areas of basic terminology, common technologies, and complete devices with core components - a progression the NMPA characterized as moving from single-point breakthroughs to systematic construction.

China has published three BCI medical device industry standards, initiated 10 national standards and three industry standards, and submitted one international standard proposal to the ISO. In April 2026, a China-led international BCI standard was released with contributions from eight countries, including the United States, Japan, and Australia, which supplied more than 300 revision comments.

Analysis: Standard-Setting as Industrial Policy

The timing reflects a deliberate strategy of “standards first” rather than waiting for technology to mature. “Technology advances by leaps and bounds; standards cannot wait until the technology matures,” People’s Daily wrote. “They should be laid out with appropriate foresight, acting as the industry’s baton and safety valve.”

This approach carries both domestic and international significance. Domestically, a unified data format is a prerequisite for algorithm development, and standardized requirements can raise research efficiency. It also opens the door to large-scale efficacy validation and seamless data transfers when patients move between hospitals. Internationally, China’s leadership in drafting BCI standards signals an ambition to help define the global rules for a technology still in its commercial infancy - a pattern increasingly visible across China’s frontier industries.

The regulatory groundwork has advanced in parallel with commercialization. Market observers widely view 2026 as China’s first year of BCI commercialization: the world’s first invasive device has been approved, semi-invasive and flexible-electrode research is accelerating, and some patients are already benefiting. In one clinical example, Peking University International Hospital implanted the world’s first rechargeable, sensing, closed-loop brain pacemaker in a 75-year-old female Parkinson’s patient, who was discharged successfully.

What’s Next

The NMPA said it will continue to track technological and industrial developments and refine the BCI medical device standards system. Under the Ministry of Industry and Information Technology’s draft National BCI Industry Standard System Construction Guide (2026 version), China targets 40-plus standards by 2028, more than 10 international standards led or participated in, and a basic BCI standards system by 2030.

With the new standard taking effect in September 2027, the coming months will test whether a compliance threshold for data quality can keep pace with a field moving faster than regulation typically allows - and whether China’s early standard-setting lead translates into lasting influence over how the global BCI industry is governed.